vs
Side-by-side financial comparison of Telesat Corp (TSAT) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
Telesat Corp is the larger business by last-quarter revenue ($73.8M vs $57.2M, roughly 1.3× Vanda Pharmaceuticals Inc.). Telesat Corp runs the higher net margin — -119.8% vs -246.8%, a 126.9% gap on every dollar of revenue. Over the past eight quarters, Vanda Pharmaceuticals Inc.'s revenue compounded faster (9.8% CAGR vs -64.0%).
Telesat, formerly Telesat Canada, is a Canadian satellite communications company founded on May 2, 1969. The company is headquartered in Ottawa.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
TSAT vs VNDA — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $73.8M | $57.2M |
| Net Profit | $-88.4M | $-141.2M |
| Gross Margin | 95.3% | — |
| Operating Margin | 5.9% | -70.5% |
| Net Margin | -119.8% | -246.8% |
| Revenue YoY | — | 7.6% |
| Net Profit YoY | — | -2774.3% |
| EPS (diluted) | — | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $57.2M | ||
| Q3 25 | $73.8M | $56.3M | ||
| Q2 25 | $77.5M | $52.6M | ||
| Q1 25 | $152.2M | $50.0M | ||
| Q4 24 | — | $53.2M | ||
| Q3 24 | — | $47.7M | ||
| Q2 24 | $363.2M | $50.5M | ||
| Q1 24 | — | $47.5M |
| Q4 25 | — | $-141.2M | ||
| Q3 25 | $-88.4M | $-22.6M | ||
| Q2 25 | $55.1M | $-27.2M | ||
| Q1 25 | $-52.3M | $-29.5M | ||
| Q4 24 | — | $-4.9M | ||
| Q3 24 | — | $-5.3M | ||
| Q2 24 | $547.4M | $-4.5M | ||
| Q1 24 | — | $-4.1M |
| Q4 25 | — | — | ||
| Q3 25 | 95.3% | — | ||
| Q2 25 | 95.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -70.5% | ||
| Q3 25 | 5.9% | -55.6% | ||
| Q2 25 | 16.8% | -73.2% | ||
| Q1 25 | — | -82.0% | ||
| Q4 24 | — | -19.3% | ||
| Q3 24 | — | -23.1% | ||
| Q2 24 | — | -20.1% | ||
| Q1 24 | — | -19.5% |
| Q4 25 | — | -246.8% | ||
| Q3 25 | -119.8% | -40.1% | ||
| Q2 25 | 71.2% | -51.7% | ||
| Q1 25 | -34.4% | -58.9% | ||
| Q4 24 | — | -9.2% | ||
| Q3 24 | — | -11.2% | ||
| Q2 24 | 150.7% | -9.0% | ||
| Q1 24 | — | -8.7% |
| Q4 25 | — | $-2.40 | ||
| Q3 25 | — | $-0.38 | ||
| Q2 25 | — | $-0.46 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.09 | ||
| Q2 24 | — | $-0.08 | ||
| Q1 24 | — | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $352.3M | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.6B | $327.2M |
| Total Assets | $5.1B | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $84.9M | ||
| Q3 25 | $352.3M | $70.0M | ||
| Q2 25 | $399.6M | $81.0M | ||
| Q1 25 | $552.1M | $111.8M | ||
| Q4 24 | — | $102.3M | ||
| Q3 24 | — | $100.5M | ||
| Q2 24 | $1.7B | $103.0M | ||
| Q1 24 | — | $125.2M |
| Q4 25 | — | $327.2M | ||
| Q3 25 | $1.6B | $466.0M | ||
| Q2 25 | $1.7B | $486.3M | ||
| Q1 25 | $2.5B | $511.4M | ||
| Q4 24 | — | $538.5M | ||
| Q3 24 | — | $541.2M | ||
| Q2 24 | $2.4B | $542.5M | ||
| Q1 24 | — | $544.0M |
| Q4 25 | — | $488.9M | ||
| Q3 25 | $5.1B | $601.1M | ||
| Q2 25 | $4.9B | $624.7M | ||
| Q1 25 | $6.9B | $631.9M | ||
| Q4 24 | — | $656.2M | ||
| Q3 24 | — | $645.1M | ||
| Q2 24 | $6.3B | $651.4M | ||
| Q1 24 | — | $652.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-29.4M |
| Free Cash FlowOCF − Capex | — | $-29.5M |
| FCF MarginFCF / Revenue | — | -51.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-29.4M | ||
| Q3 25 | — | $-31.6M | ||
| Q2 25 | — | $-15.3M | ||
| Q1 25 | — | $-33.1M | ||
| Q4 24 | — | $-1.8M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-6.9M | ||
| Q1 24 | — | $7.6M |
| Q4 25 | — | $-29.5M | ||
| Q3 25 | — | $-31.8M | ||
| Q2 25 | — | $-15.6M | ||
| Q1 25 | — | $-33.6M | ||
| Q4 24 | — | $-2.0M | ||
| Q3 24 | — | $-14.7M | ||
| Q2 24 | — | $-7.0M | ||
| Q1 24 | — | $7.6M |
| Q4 25 | — | -51.6% | ||
| Q3 25 | — | -56.5% | ||
| Q2 25 | — | -29.6% | ||
| Q1 25 | — | -67.1% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | — | -30.9% | ||
| Q2 24 | — | -13.9% | ||
| Q1 24 | — | 15.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TSAT
Segment breakdown not available.
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
